Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

BACKGROUND: The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulation. We conducted a phase 0/I clinical trial in an adjuvan...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res
Autori principali: Quintela-Fandino, Miguel, Apala, Juan V., Malon, Diego, Mouron, Silvana, Hornedo, Javier, Gonzalez-Cortijo, Lucia, Colomer, Ramon, Guerra, Juan
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534834/
https://ncbi.nlm.nih.gov/pubmed/31126332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1152-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi